WHITE PAPER

# NAVIGATING FDA 510(K) PATHWAYS FOR AI/ML IN MEDICAL DEVICES: A STRATEGIC GUIDE FOR DIGITAL TRANSFORMATION

Infosys®
Navigate your next

## Executive Summary

The convergence of artificial intelligence and machine learning with medical device technology represents one of healthcare's most transformative opportunities. As regulatory frameworks evolve to accommodate these dynamic technologies, organizations face complex challenges in navigating FDA approval pathways while maintaining competitive advantage.

This whitepaper examines the FDA 510(k) premarket notification pathway for AI/ML-enabled medical devices, providing strategic insights for technology leaders, healthcare organizations, and medical device manufacturers. We explore critical regulatory considerations including Total Product Lifecycle (TPLC) management, Predetermined Change Control Plans (PCCP), and comprehensive risk frameworks that enable safe, effective deployment of intelligent medical solutions.

Key findings reveal that successful AI/ML medical device approval requires sophisticated data governance, algorithm transparency, robust validation methodologies, and proactive cybersecurity measures. Organizations that understand these requirements can accelerate time-to-market while ensuring regulatory compliance and patient safety.

The FDA has cleared over 850 AI/ML-enabled devices through May 2024, with 96% achieving approval through the 510(k) pathway. This trend demonstrates both the viability of the regulatory approach and the growing acceptance of intelligent medical technologies in clinical practice.

Through strategic technology partnerships and deep regulatory expertise, organizations can navigate these complex requirements while building sustainable innovation capabilities that drive meaningful healthcare outcomes.

## Table of Contents

## 1. Introduction: The AI Revolution in Medical Devices

Healthcare technology stands at an inflection point. Artificial intelligence and machine learning are fundamentally reshaping how we diagnose, treat, and manage patient care. These technologies promise unprecedented improvements in clinical accuracy, operational efficiency, and patient outcomes.

Yet realizing this potential requires more than technical excellence. It demands sophisticated understanding of regulatory pathways, strategic navigation of complex approval processes, and deep expertise in compliance frameworks that govern medical device innovation.

The FDA 510(k) premarket notification pathway serves as the primary regulatory gateway for most AI/ML-enabled medical devices entering the US market. This pathway, originally designed for static devices, has evolved to accommodate the dynamic nature of intelligent systems that learn and adapt over time.

Understanding this evolution is critical for organizations seeking to bring AI/ML medical devices to market. The regulatory landscape presents both opportunities and challenges that require strategic approach, technical expertise, and proactive engagement with regulatory frameworks.

This whitepaper provides comprehensive guidance for navigating these complexities, drawing on deep industry expertise and regulatory knowledge to help organizations accelerate their AI/ML medical device initiatives while ensuring patient safety and regulatory compliance.

## The Strategic Imperative

Organizations across the healthcare ecosystem recognize AI/ML's transformative potential. However, many struggle with the regulatory complexities that govern medical device approval. The intersection of rapidly evolving technology and established regulatory frameworks creates unique challenges that demand specialized expertise.

Success requires more than compliance. It requires strategic thinking about how AI/ML technologies integrate with existing healthcare systems, how they evolve over time, and how they deliver measurable value to patients and providers.

## 2. Understanding FDA 510(k) Regulatory Framework




### 2.1 Foundation of 510(k) Premarket Notification

The FDA 510(k) pathway represents a critical regulatory mechanism for medical device approval in the United States. This premarket notification process requires manufacturers to demonstrate that their device is "substantially equivalent" to a legally marketed predicate device.

Unlike Premarket Approval (PMA), which requires independent validation of safety and efficacy, the 510(k) pathway results in device "clearance" rather than "approval." This distinction reflects the pathway's focus on comparative analysis rather than absolute validation.

The 510(k) pathway primarily applies to moderate-risk Class II devices and some non-exempt Class I devices. This scope encompasses the majority of AI/ML-enabled medical devices currently entering the market, making the pathway essential for organizations developing intelligent healthcare solutions.

### 2.2 Substantial Equivalence and Predicate Selection

Substantial equivalence forms the cornerstone of 510(k) submissions. A device achieves substantial equivalence when it shares the same intended use as a legally marketed predicate device and either employs identical technological characteristics or different characteristics that do not raise new safety and effectiveness concerns.

For AI/ML devices, establishing substantial equivalence presents unique challenges. Traditional predicate devices may lack the dynamic characteristics of intelligent systems, requiring careful analysis of technological differences and their implications for safety and effectiveness.

Successful predicate selection requires deep understanding of both the proposed device's capabilities and the regulatory history of similar technologies. This analysis must consider not only current functionality but also the device's potential evolution through learning algorithms.

### 2.3 Submission Types and Strategic Considerations

The FDA recognizes three primary 510(k) submission types, each serving different strategic purposes:

**Traditional 510(k)** submissions represent the most common pathway for new devices seeking substantial equivalence to existing predicate devices. These submissions require comprehensive documentation of device characteristics, performance data, and comparative analysis.

**Special 510(k)** submissions apply to modifications of previously cleared devices where intended use and fundamental technology remain unchanged. This pathway offers streamlined review for organizations updating existing products.

**Abbreviated 510(k)** submissions leverage FDA-recognized standards and guidance documents to streamline the demonstration of substantial equivalence. This pathway can reduce submission complexity when applicable standards exist.

For AI/ML devices, traditional submission approaches may prove insufficient due to the dynamic nature of intelligent systems. This limitation has driven development of new regulatory mechanisms specifically designed for adaptive technologies.

# 3. AI/ML Integration: Unique Characteristics and Challenges

## 3.1 Defining AI/ML in Healthcare Context

AI/ML systems in healthcare encompass technologies that can perceive, interpret, learn, and make decisions based on data inputs. These systems excel at discovering complex patterns and correlations that may not be apparent to human analysis, making them particularly valuable for diagnostic and decision-support applications.

Machine learning algorithms enable medical devices to improve performance over time through exposure to new data and real-world experience. This adaptive capability represents both the greatest opportunity and the primary regulatory challenge for AI/ML medical devices.

The FDA has cleared numerous AI/ML devices that demonstrate this potential, including:

**IDx-DR**
for automated diabetic retinopathy detection

**OsteoDetect**
for wrist fracture identification

**ContaCT**
for stroke detection and specialist alerting

**Guardian Connect**
for continuous glucose monitoring

**FibriCheck**
for atrial fibrillation detection using mobile devices

These examples illustrate the breadth of AI/ML applications across medical specialties and the regulatory pathway's ability to accommodate diverse technological approaches.

## 3.2 Regulatory Challenges of Dynamic Systems

AI/ML systems present fundamentally different regulatory challenges compared to traditional medical devices. Unlike static systems with fixed functionality, AI/ML devices can evolve aftermarket release through continuous learning algorithms.

This dynamic nature raises critical concerns about performance drift, algorithmic bias, and unexpected behavioral changes. Traditional regulatory frameworks, designed for static devices, struggle to address these evolving characteristics.

Key challenges include:



**Performance Drift**
AI/ML systems may exhibit changing performance characteristics as they encounter new data patterns or edge cases not present in original training datasets.

**Algorithmic Bias**
Training data limitations or imbalances can introduce systematic biases that may amplify health disparities or reduce effectiveness across diverse patient populations.

**Explainability**
Many AI/ML systems, particularly deep learning models, function as "black boxes" with decision-making processes that are difficult to interpret or explain.

**Validation Complexity**
Traditional validation approaches may prove insufficient for systems that change over time, requiring new methodologies for ongoing performance assessment.

These challenges demand innovative regulatory approaches that balance innovation enablement with patient safety protection.

## 3.3 The Transparency Imperative

The FDA emphasizes the critical importance of algorithm transparency and explainability. This requirement extends beyond technical accuracy to encompass clear communication of how AI systems function, their limitations, and strategies for risk mitigation.

Regulatory submissions must address not only technical specifications but also ethical considerations, user-centered design principles, and comprehensive strategies for ensuring AI systems remain transparent and trustworthy throughout their lifecycle.

This transparency imperative reflects growing recognition that successful AI/ML deployment requires not only technical excellence but also stakeholder confidence and clinical acceptance.

# 4. FDA's Strategic Approach to AI/ML Technologies

## 4.1 Comprehensive Regulatory Evolution

The FDA has proactively developed a comprehensive strategic approach to AI/ML regulation, aligning with broader government initiatives including Executive Order 14110 from October 2023, which directed the Department of Health & Human Services to develop strategic AI frameworks.

This strategic approach encompasses multiple initiatives designed to address the unique characteristics of AI/ML technologies while maintaining rigorous safety standards:




## 4.2 Good Machine Learning Practice (GMLP) Principles

The GMLP principles represent international regulatory harmonization efforts, establishing foundational standards for AI/ML medical device development:




These principles establish a framework for responsible AI/ML development that balances innovation with safety requirements.

## 4.3 Total Product Lifecycle (TPLC) Framework

The FDA's TPLC framework represents a paradigm shift from traditional one-time device evaluation to continuous lifecycle management. This approach acknowledges that AI/ML devices require ongoing monitoring and potential modification throughout their operational life.

Critical TPLC components include:

**User Interface & Labeling:**

Clear communication of AI capabilities, target users, and training requirements ensures appropriate utilization.

**Risk Assessment:**

Early integration of risk management and human factors considerations mitigates AI-specific risks including bias and system failures.

**Data Management:**

Comprehensive frameworks for data quality, integrity, and security throughout the device lifecycle.

**Model Transparency:**

Documentation of model structure, decision logic, and performance characteristics enables understanding and trust.

**Validation:**

Extensive testing across diverse populations and real-world environments, including clinical and usability validation.

**Device Performance Monitoring:**

Robust mechanisms for monitoring device performance across varied real-world environments post-deployment.

**Cybersecurity:**

Comprehensive security measures including encryption and secure access protocols to protect against data breaches and ensure model integrity.

**Public Submission Summary:**

Transparent, publicly accessible summaries of AI device characteristics enhance stakeholder understanding and trust.

# 5. Predetermined Change Control Plans: Enabling Adaptive Systems

## 5.1 PCCP Framework Overview

Predetermined Change Control Plans (PCCPs) represent a groundbreaking regulatory innovation designed specifically for AI/ML medical devices. Traditional regulatory approaches require new premarket submissions for any significant device modifications, creating barriers for adaptive systems that must evolve to maintain optimal performance.

PCCPs enable manufacturers to submit proactive, formal plans defining specific types of changes that may be implemented without additional regulatory submissions. After FDA review and approval, authorized PCCPs allow predefined modifications while maintaining regulatory oversight and patient safety protection.

This forward-looking approach specifically addresses AI/ML technologies where iterative improvement and updates are essential for maintaining performance and safety. PCCPs accommodate both automated changes resulting from continuous learning algorithms and manual updates involving human oversight.

## 5.2 Essential PCCP Components

Successful PCCP submissions require three critical elements:

**Description of Modifications:**

Comprehensive definition of intended AI-DSF modifications including their nature (automatic or manual), scope (universal or localized), and performance specifications. Modifications must be specific, measurable, and verifiable to enable effective oversight.

**Modification Protocol:**

Detailed methodology for creating, validating, and implementing defined changes. This includes verification procedures, acceptance criteria, data handling protocols, algorithm retraining processes, performance assessment methodologies, and revision procedures ensuring continued safety and efficacy.

**Impact Assessment:**

Thorough evaluation of proposed changes' risks and benefits. This assessment contrasts the modified device with its original state, anticipates potential issues including bias concerns, and outlines comprehensive mitigation strategies. Cumulative change evaluation ensures device integrity preservation over time.

## 5.3 Implementation Strategy and Post-Authorization Management

AI/ML devices with authorized PCCPs must initially achieve premarket approval through standard FDA pathways (PMA, 510(k), or De Novo). The FDA evaluates both the device and all PCCP-defined changes for safety, effectiveness, or substantial equivalence.

Post-authorization, manufacturers must implement changes strictly according to authorized PCCP specifications and quality system compliance requirements. Changes falling within approved Description of Modifications and following approved Modification Protocols require no new submissions, though comprehensive documentation remains mandatory.

Departures from designated PCCPs or modifications to PCCPs themselves typically require new marketing submissions. However, Special 510(k) submissions may suffice when established evaluation methods apply.

Early FDA engagement is strongly recommended, particularly for combination products or high-risk devices. The Q-Submission Program provides valuable feedback on proposed PCCPs prior to formal submission.

# 6. Critical Considerations for AI/ML Device Submissions

## 6.1 Data Foundation and Quality Management

Successful AI/ML device submissions require unprecedented attention to data quality and management throughout the development lifecycle. The foundation of any AI/ML system lies in the quality, representativeness, and integrity of its training and validation datasets.

**Data Quality Standards:**

Training datasets must meet rigorous quality standards including completeness, accuracy, and consistency. Data cleaning and preprocessing procedures require comprehensive documentation to demonstrate systematic bias mitigation and quality assurance.

**Population Representativeness:**

Datasets must adequately represent the intended use population across relevant demographic, geographic, and clinical characteristics. This representation is critical for ensuring device performance across diverse patient populations and preventing algorithmic bias.

**Data Governance Frameworks:**

Comprehensive data governance encompasses data collection protocols, storage security, access controls, version management, and audit trails. These frameworks ensure data integrity throughout the device lifecycle.

**Real-World Evidence Integration:**

Incorporating real-world data and evidence strengthens validation and demonstrates device performance in actual clinical environments beyond controlled study conditions.

## 6.2 Algorithm Development and Validation

AI/ML algorithm development and validation require specialized methodologies that address the unique characteristics of learning systems.

**Algorithm Architecture:**

Clear documentation of algorithm architecture, including model selection rationale, hyperparameter optimization, and training methodology enables regulatory review and clinical understanding.

**Performance Metrics:**

Appropriate performance metrics must align with clinical endpoints and intended use claims. Metrics should address not only accuracy but also precision, recall, specificity, and potential failure modes.

**Validation Methodologies:**

Traditional validation approaches may prove insufficient for AI/ML systems. Cross-validation, holdout testing, and real-world validation provide comprehensive performance assessment across different data conditions.

**Bias Detection and Mitigation:**

Systematic approaches for identifying and mitigating algorithmic bias ensure equitable performance across diverse patient populations. This includes fairness metrics and bias testing protocols.

## 6.3 Risk Management and Cybersecurity

AI/ML medical devices require comprehensive risk management frameworks that address both traditional medical device risks and AI-specific considerations.

**AI-Specific Risk Analysis:**

Risk analysis must consider unique AI/ML risks including adversarial attacks, data poisoning, model inversion, and performance degradation over time.

**Cybersecurity Frameworks:**

Robust cybersecurity measures protect against threats to data integrity, model integrity, and system availability. This includes encryption, access controls, threat monitoring, and incident response protocols.

**Human Factors Engineering:**

User interface design and human factors considerations ensure appropriate interaction between clinical users and AI/ML systems. This includes alert management, decision support presentation, and override capabilities.

**Post-Market Surveillance:**

Comprehensive post-market surveillance programs monitor device performance, identify potential issues, and enable rapid response to safety concerns.

## 6.4 Clinical Evidence and Real-World Performance

Clinical evidence requirements for AI/ML devices encompass both traditional clinical validation and AI-specific performance demonstration.

**Usability Studies:**

Human factors studies ensure that AI/ML systems integrate effectively with clinical workflows and decision-making processes.

**Real-World Performance Monitoring:**

Ongoing monitoring of device performance in real-world clinical environments enables detection of performance drift and validation of continued effectiveness.

**Clinical Validation:**

Clinical studies must demonstrate device safety and effectiveness in intended use environments with appropriate patient populations and clinical workflows.



**Comparative Effectiveness:**

Where appropriate, comparative studies demonstrate AI/ML device performance relative to current standard of care or alternative diagnostic approaches.

# 7. Current Market Landscape and Future Trends

## 7.1 FDA Approval Trends and Market Growth

The AI/ML medical device market has experienced remarkable growth, with the FDA clearing over 850 AI/ML-enabled devices through May 2024. This represents exponential growth from just six clearances in 2015 to 221 in 2023 alone.

Significantly, 96% of these devices achieved clearance through the 510(k) pathway, demonstrating the pathway's effectiveness for AI/ML technologies. Radiology leads adoption, reflecting the specialty's digital readiness and clear use cases for AI assistance.

**Leading Companies and Market Concentration:**

Market leaders include established medical technology companies and innovative AI-focused startups. Companies like Aidoc, Arterys, Caption Health, and numerous others have successfully navigated regulatory pathways to bring AI/ML solutions to market.



**Specialty Distribution:**

While radiology dominates current approvals, AI/ML applications are expanding across specialties including cardiology, ophthalmology, pathology, and primary care. This expansion reflects growing clinical acceptance and recognition of AI/ML value across medical disciplines.

## 7.2 Technology Evolution and Regulatory Adaptation

The AI/ML medical device landscape continues evolving rapidly, with new technologies and applications emerging regularly. Several trends shape future development:

**Real-World Evidence Integration:**

The FDA increasingly incorporates real-world evidence into regulatory decision-making, enabling more comprehensive understanding of device performance across diverse clinical environments.

**Global Regulatory Harmonization:**

Collaborative efforts between FDA, Health Canada, and MHRA are creating internationally harmonized standards through GMLP principles, potentially streamlining global market access.

**Patient-Centered and Ethical AI:**

Growing emphasis on transparency, ethical development, and stakeholder engagement ensures AI systems deliver meaningful patient value while addressing concerns about bias and accessibility.

**Continuous Learning Challenges:**

Adaptive algorithms present ongoing challenges around validation maintenance and performance monitoring. The FDA's TPLC and PCCP frameworks address these challenges but require continued refinement.

## 7.3 Emerging Technologies and Future Opportunities

Several emerging technologies and application areas represent significant future opportunities:

**Generative AI Applications:**

While generative AI has not yet moved extensively into regulated medical device space, potential applications in medical imaging, drug discovery, and clinical decision support represent significant future opportunities.

**Multi-Modal AI Systems:**

AI systems integrating multiple data types (imaging, laboratory, clinical, genomic) offer enhanced diagnostic and therapeutic capabilities but present complex validation challenges.

**Edge Computing and Distributed AI:**

AI systems operating at the point of care through edge computing enable real-time decision support but require new approaches to validation and quality assurance.

**Federated Learning:**

Collaborative learning approaches that preserve data privacy while enabling algorithm improvement across multiple institutions present both opportunities and regulatory challenges.

# 8. Strategic Recommendations for Organizations

## 8.1 Building Regulatory Expertise and Capabilities

Organizations developing AI/ML medical devices must invest in specialized regulatory expertise that goes beyond traditional medical device knowledge. This expertise encompasses understanding of AI/ML-specific regulatory requirements, data governance, and lifecycle management.

**Early Regulatory Engagement:**

Proactive engagement with FDA through pre-submission meetings, Q-Submission programs, and guidance document participation enables early understanding of regulatory expectations and requirements.

**Cross-Functional Team Development:**

Successful AI/ML device development requires cross-functional teams including clinical experts, data scientists, regulatory professionals, quality assurance specialists, and cybersecurity experts.

**Regulatory Intelligence:**

Ongoing monitoring of regulatory developments, guidance updates, and industry precedents enables proactive adaptation to evolving requirements.

## 8.2 Data Strategy and Infrastructure Investment

Robust data strategies form the foundation for successful AI/ML medical device development and regulatory approval.



**Data Quality Infrastructure:**

Investment in data quality management systems, validation frameworks, and governance processes ensures regulatory compliance and algorithm performance.

**Real-World Data Capabilities:**

Developing capabilities for real-world evidence generation and analysis enables comprehensive device validation and post-market monitoring.

**Data Security and Privacy:**

Comprehensive data security frameworks protect sensitive healthcare information while enabling necessary data access for algorithm development and validation.

## 8.3 Technology Partnership Strategy

Strategic technology partnerships can accelerate AI/ML medical device development while reducing risks and costs.

**Regulatory Consulting:**

Partnerships with specialized regulatory consulting firms provide access to deep expertise and regulatory intelligence without requiring full internal capability development.

**Technology Platform Partnerships:**

Collaborations with established technology platforms can provide validated infrastructure, reducing development time and regulatory complexity.

**Clinical Partnership Networks:**

Relationships with healthcare systems and clinical research organizations enable access to diverse patient populations and real-world validation opportunities.

## 8.4 Lifecycle Management and Quality Systems

AI/ML medical devices require sophisticated lifecycle management approaches that address their dynamic characteristics.

**Quality Management Systems:**

QMS frameworks must address AI/ML-specific requirements including algorithm versioning, performance monitoring, and change control processes.

**Post-Market Surveillance:**

Comprehensive surveillance programs enable early detection of performance issues and demonstrate ongoing device safety and effectiveness.

**Continuous Improvement:**

Systematic approaches to device improvement through real-world learning while maintaining regulatory compliance and patient safety.

# 9. Conclusion: Accelerating Innovation Through Intelligent Navigation

The convergence of artificial intelligence and medical device technology represents one of healthcare's most significant transformation opportunities. Organizations that successfully navigate the regulatory complexity surrounding AI/ML medical devices will gain substantial competitive advantage while contributing to improved patient outcomes.

The FDA 510(k) pathway has proven both viable and effective for AI/ML medical device approval, with over 850 devices cleared through this route. However, success requires sophisticated understanding of regulatory requirements, proactive approach to compliance, and strategic investment in specialized capabilities.

Key success factors include:

**Comprehensive Data Strategy:**

High-quality, representative datasets form the foundation for successful AI/ML device development and regulatory approval. Organizations must invest in robust data governance frameworks and quality management systems.

**Regulatory Expertise:**

Specialized knowledge of AI/ML regulatory requirements, including PCCP development, TPLC management, and risk assessment methodologies, is essential for successful submissions.

**Technology Excellence:**

Technical excellence in algorithm development, validation methodologies, and cybersecurity measures ensures device safety and effectiveness while meeting regulatory standards.

**Strategic Partnerships:**

Collaborations with regulatory experts, technology platforms, and clinical networks can accelerate development while reducing risks and costs.

**Lifecycle Management:**

Sophisticated approaches to device lifecycle management address the dynamic characteristics of AI/ML systems while maintaining regulatory compliance.

The regulatory landscape will continue evolving as AI/ML technologies advance and clinical experience grows. Organizations that establish strong foundations now will be positioned to capitalize on future opportunities while maintaining competitive advantage.

Through strategic approach, technical excellence, and deep regulatory understanding, organizations can successfully navigate the FDA 510(k) pathway for AI/ML medical devices, accelerating innovation while ensuring patient safety and regulatory compliance.

The future of healthcare lies in the intelligent integration of AI/ML technologies with clinical practice. Organizations that master this integration will lead the transformation of healthcare delivery, improving outcomes for patients while building sustainable competitive advantage in the evolving healthcare technology landscape.

## References


- Access Data FDA. (2024). [Database of FDA Medical Device Clearances]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
- FDA. (2021a). FDA Releases Artificial Intelligence/Machine Learning (AI/ML)-Based Software Action Plan. https://www.fda.gov/news-events/press-announcements/fda-releases-artificial-intelligencemachine-learning-action-plan
- FDA. (2021b). Good Machine Learning Practice for Medical Device Development: Guiding Principles. https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles
- FDA. (2023a). FDA Completes First AI-Assisted Scientific Review Pilot. https://www.fda.gov/news-events/press-announcements/fda-announces-completion-first-ai-assisted-scientific-review-pilot-and-aggressive-agency-wide-ai
- FDA. (2023b). Discussion Papers on Artificial Intelligence Use in Healthcare. https://www.fda.gov/news-events/fda-voices/fda-releases-two-discussion-papers-spur-conversation-about-artificial-intelligence-and-machine
- FDA. (2024a). Marketing Submission Recommendations for Predetermined Change Control Plans for AI/ML. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence
- FDA. (2024b). Artificial Intelligence-Enabled Device Software Functions Lifecycle Management and Marketing. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing
- FDA. (2024c). Real-World Evidence. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- FDA. (2025a). Draft Guidance on AI-Enabled Device Software Functions. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing
- FDA. (2025b). AI Device Transparency and Bias Mitigation Strategies (Draft Guidance). https://www.fda.gov/news-events/press-announcements/fda-issues-comprehensive-draft-guidance-developers-artificial-intelligence-enabled-medical-devices
- MedTech Dive. (2024). FDA clears record number of AI medical devices. https://www.medtechdive.com/news/fda-ai-medical-devices-growth/728975/
- The FDA Group. (2022). PMA vs. 510(k) Submission Process. https://www.thefdagroup.com/blog/pma-vs-510k
- The Pew Charitable Trusts. (2021). AI and Medical Products Issue Brief. https://www.pew.org/-/media/assets/2021/08/ai_medicalproducts_issuebrief_final.pdf
- USDM. (2022). Good Machine Learning Practice (GMLP) for Medical Device Development. https://usdm.com/resources/blogs/good-machine-learning-practice-gmlp-for-medical-device-development-guiding-principals
- White House. (2024). Executive Order 14110: Advancing Governance, Innovation, and Risk Management for Agency Use of Artificial Intelligence. https://www.whitehouse.gov/wp-content/uploads/2024/03/M-24-10-Advancing-Governance-Innovation-and-Risk-Management-for-Agency-Use-of-Artificial-Intelligence.p


## About the Authors


### Ankita Khanna

**Digital Solution Specialist, Engineering Services, Infosys**

### Manish Snehi

**Senior Technology Architect, Engineering Services, Infosys**



For more information, contact askus@infosys.com


Infosys®
Navigate your next